Aubrey de Grey

Aubrey de Grey

Company: SENS Research Foundation

Job title: Founder & Chief Scientific Officer

Bio:

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits (uncompensated) on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Seminars:

Panel Discussion: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities 4:30 pm

Examining what we do and do not know about the aging process Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions Analyzing the current R&D landscape for anti-aging therapeutics Discussing recent breakthroughs and the growing interest in this space – attracting funding/ partnerships, important learnings to date…Read more

day: Day One

Rejuvenation Biotechnology: How Can the PhDs Help the MDs & the MBAs? 2:15 pm

Discover how one by one, anti-aging damage repair therapies are moving into (expensive) clinical trials Most clinical trials fail: Discuss how the rejuvenation biotechnology sector will be no different Why do investors often oversimplify and lose nerve? Could this badly delay availability of powerful therapies? Examine why researchers have huge influence over general-audience sentiment and…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.